Browsing by Author "Hernández-Boluda, Juan Carlos"

Sort by: Order: Results:

  • Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
    Hernández-Boluda, Juan Carlos; Angona Figueras, Anna; Steegmann, Juan Luis; Grupo Español de Leucemia Mieloide Crónica (GELMC) (Nature Publishing Group, 2018)
    Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not lose the major molecular response (MMR) after stopping treatment with tyrosine kinase inhibitors (TKI). This strategy is safe in clinical ...
  • Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea
    Alvarez-Larrán, Alberto; Díaz-González, Alvaro; Such, Esperanza; Mora, Elvira; Andrade-Campos, Marcio; García-Hernández, Carmen; Gómez-Casares, Maria-Teresa; García-Gutiérrez, Valentín; Carreño-Tarragona, Gonzalo; Garrote, Marta; Fernández-Ibarrondo, Lierni; Cervera, José; Bellosillo Paricio, Beatriz; Cervantes, Francisco; Hernández-Boluda, Juan Carlos; MPN Spanish Group (GEMFIN) (Nature Research, 2020)
  • Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology
    Garrote, Marta; López-Guerra, Mónica; García-Pagán, Joan Carles; Arellano-Rodrigo, Eduardo; Ferrer-Marín, Francisca; Hernández-Boluda, Juan Carlos; Bellosillo Paricio, Beatriz; Nomdedeu, Meritxell; Hernández-Gea, Virginia; Triguero, Ana; Guijarro, Francesca; Álamo, José; Baiges Aznar, Anna; Turon, Fanny; Colomer Pujol, Dolors; Cervantes, Francisco; Alvarez-Larrán, Alberto (Springer, 2024)
    To elucidate the role of splanchnic vein thrombosis (SVT) and genomic characteristics in prognosis and survival, we compared patients with polycythemia vera (PV) or essential thrombocythemia (ET) presenting SVT at diagnosis ...
  • Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia
    Alvarez-Larrán, Alberto; Senín Magan, Maria Alicia; Fernández Rodríguez, M. Concepción; Pereira, Arturo; Arellano-Rodrigo, Arturo; Gómez, Montse; Ferrer-Marín, Francisca; Martínez-López, Joaquín; Camacho Díaz, Laura; Colomer Pujol, Dolors; Angona Figueras, Anna; Navarro, Blanca; Cervantes, Francisco; Besses Raebel, Carles; Bellosillo Paricio, Beatriz; Hernández-Boluda, Juan Carlos (Wiley, 2017)
    The influence of driver mutations on leukaemic transformation was analysed in 1747 patients with polycythaemia vera or essential thrombocythaemia. With a median follow-up of 7·2 years, 349 patients died and 62 progressed ...
  • Impact of individual comorbidities on survival of patients with myelofibrosis
    García-Fortes, María; Hernández-Boluda, Juan Carlos; Alvarez-Larrán, Alberto; Raya, José M.; Angona Figueras, Anna; Estrada, Natalia; Fox, Laura; Cuevas, Beatriz; García-Hernández, María C.; Gómez-Casares, Maria-Teresa; Ferrer-Marín, Francisca; Saavedra, Silvana; Cervantes, Francisco; García-Delgado, Regina; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas Gemfin (MDPI, 2022)
    The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on ...
  • Machine learning improves risk stratification in myelofibrosis: An analysis of the spanish registry of myelofibrosis
    Mosquera Orgueira, Adrián; Vélez, Patricia; Bellosillo Paricio, Beatriz; Hernández-Boluda, Juan Carlos (Wolters Kluwer (LWW), 2022)
    Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking